铜蓝蛋白与上皮性卵巢癌化疗耐药及复发的关系  

Study on the correlation between ceruloplasmin expression and chemotherapy resistance and recurrence in epithelial ovarian cancer

作　　者：秦倩 马睿[1] 魏斌 秘嘉庆 尚云 冯勤梅[2] QIN Qian;MA Rui;WEI Bin;MI Jia-qing;SHANG Yun;FENG Qin-mei(Department of Obstetrics and Gynecology,Yuncheng Central Hospital Affiliated to Shanxi Medical University,Yuncheng 044099,Shanxi,China;不详)

机构地区：[1]山西医科大学附属运城市中心医院妇产科,山西运城044099 [2]山西省人民医院妇产科,山西太原030012

出　　处：《广东医学》2025年第2期245-250,共6页Guangdong Medical Journal

基　　金：运城市2023年科技计划项目(YCKJ-2023053)。

摘　　要：目的通过免疫组化检测铜蓝蛋白(Cp)在不同卵巢组织中的表达情况,进一步结合临床病例分析,探讨上皮性卵巢癌(EOC)中Cp表达水平及其与化疗耐药和复发的关系。方法收集2015年1月至2018年12月在山西省人民医院妇科初次手术治疗且经病理科诊断为EOC的组织样本127份,同时收集同期卵巢交界性肿瘤组织样本67份,卵巢良性肿瘤以及正常卵巢组织样本各30份,免疫组化(IHC)SP法测定不同卵巢组织中Cp表达情况,并通过卡方检验比较其表达差异;随后收集临床病例和随访资料并根据美国妇科肿瘤学组(GOG)的标准将研究对象分为铂类敏感组、铂类部分敏感组和铂类耐药组,χ^(2)检验分析Cp与EOC化疗耐药及复发相关临床特征的关系,通过单因素和多因素Cox回归分析EOC复发的独立危险因素,并经K-M生存曲线分析Cp表达对患者复发时间的影响。结果Cp在EOC组织中表达显著高于卵巢交界性肿瘤、卵巢良性肿瘤和正常卵巢组织(P<0.05)。Cp在化疗耐药组和部分敏感组中表达水平显著高于化疗敏感组(P<0.05)。Cp与EOC有无腹腔积液、FIGO分期、淋巴结转移、病理分级、病理类型、CA125、HE4均相关(P<0.05)。Cp表达、FIGO分期、术前HE4为EOC初治后复发的独立危险因素(P<0.05)。Cp高表达患者初治后复发时间显著缩短(P<0.05),可用来预测初治后复发。结论Cp在EOC癌组织中高表达,与化疗耐药显著相关,为复发的独立危险因素,可用来预测复发。Objective To investigate the expression levels of ceruloplasmin(Cp)in various ovarian tissues through immunohistochemistry(IHC)and to analyze its association with chemotherapy resistance and recurrence in epithelial ovarian cancer(EOC).Methods A total of 127 EOC tissue samples from patients who underwent initial surgical treatment at Shanxi Provincial People′s Hospital between January 2015 and December 2018 were collected.Additionally,67 borderline ovarian tumor samples,30 benign ovarian tumor samples,and 30 normal ovarian tissue samples were included.The expression of Cp was detected using the IHC SP method,and its differences among tissue types were compared using the chi-square test.Clinical and follow-up data were collected,and patients were classified into platinum-sensitive,partially sensitive,and platinum-resistant groups according to the standards of the Gynecologic Oncology Group(GOG).The relationship between Cp expression and chemotherapy resistance or recurrence-related clinical characteristics in EOC was analyzed using chi-square tests.Univariate and multivariate Cox regression analyses were employed to identify independent risk factors for EOC recurrence,while Kaplan-Meier survival curves assessed the impact of Cp expression on recurrence-free survival.Results Cp expression was significantly higher in EOC tissues compared to borderline tumors,benign tumors,and normal ovarian tissues(P<0.05).Cp expression levels were significantly higher in the platinum-resistant and partially sensitive groups compared to the platinum-sensitive group(P<0.05).Cp expression was significantly associated with the presence of ascites,FIGO stage,lymph node metastasis,pathological grade,histological type,and tumor markers CA125 and HE4(P<0.05).High Cp expression,advanced FIGO stage,and elevated preoperative HE4 levels were identified as independent risk factors for EOC recurrence(P<0.05).High Cp expression was associated with a significantly shorter recurrence-free survival time(P<0.05).Conclusion Cp is highly expressed in

关 键 词：铜蓝蛋白 上皮性卵巢癌 化疗耐药 复发 

分 类 号：R711[医药卫生—妇产科学] R73[医药卫生—临床医学]